VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
GERN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
GERNGeron Corporation
$1.30$834M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksGERNBalance Sheet

Geron Corporation (GERN) Balance Sheet

30Y historyFree accessUpdated daily

The company has successfully eliminated its debt as of 2026Q1, though it continues to carry a $1.9 billion accumulated deficit in retained earnings.

GERN Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets498.53M520.27M490.99M341.35M180.25M187.21M199.86M141.61M166.06M95.97M116.11M115.89M153.41M67.06M98.42M125.63M195.02M117.78M168.25M213.37M217.15M195.65M124.78M111.81M50.77M71.7M34.59M40.4M25.8M23.5M25M
Cash & Short-Term Investments314.29M359.8M406.57M333.7M172.75M183.72M196.28M139.32M163.56M94.95M115.11M114.04M151.71M65.22M96.33M121.31M186.57M111.61M162.84M206M213.33M190.47M119.96M109.25M46.99M68.94M33.02M7.8M16.4M4.1M12.4M
Cash Only70.78M79.44M79.02M70.02M56.84M34.87M9.93M13.64M10.84M16.6M13.08M21.52M43.06M12.99M22.86M16.11M45.97M34.6M109.35M146.03M135.88M96.63M9.85M12.82M4.6M18.77M29.98M7.8M16.4M4.1M12.4M
Short-Term Investments243.51M280.36M327.55M263.68M115.9M148.85M186.35M125.68M152.71M78.35M102.03M92.52M108.64M52.23M73.47M105.21M140.6M77.01M53.49M59.98M77.45M93.84M110.12M96.43M42.38M50.17M3.04M0000
Accounts Receivable039.23M38.8M1.66M3.14M1.76M722K802K1.17M436K475K1.21M963K564K752K1.4M1.8M1.32M882K788K1.27M2.3M1.7M1.21M1.14M1.52M1.21M700K500K900K0
Days Sales Outstanding53.0277.86183.932.55K1.93K461.951.04K636.37399.93149.4328.1412.1304.85160.45101.32209.3184.29278.72114.8537.74141.232.9K588.23377.13332.54153.2666.647.3126.8445-
Inventory0038.71M00000-1.17M-436K-475K-1.21M-963K0-752K0000000000530K00000
Days Inventory Outstanding610.14-11.25K----------------------------
Other Current Assets184.25M121.25M6.91M5.99M4.36M364K363K270K269K268K268K267K266K795K794K793K792K791K816K2.44M00530K530K530K703K364K31.9M8.9M18.5M12.6M
Total Non-Current Assets35.59M50.27M102.79M52.73M10.33M38.83M70.87M23.91M19.23M14.34M14.14M32.87M19.11M287K1.38M34.42M38.57M62.6M7.97M5.52M3.65M5.6M7.1M6.31M9.9M24.54M79.44M23.3M18.7M2.6M3.8M
Property, Plant & Equipment1M884K4.19M4.73M4.94M5.38M5.95M2.9M59K102K183K207K173K92K974K1.24M3.09M3.94M4.39M4.08M2.48M2.75M2.09M1.68M2.44M3.59M3.68M3.8M2.3M2.4M3M
Fixed Asset Turnover88.06x208.01x18.37x0.05x0.12x0.26x0.04x0.16x18.07x10.44x33.67x175.71x6.66x13.95x2.78x1.96x1.15x0.44x0.64x1.87x1.32x0.11x0.50x0.70x0.51x1.01x1.80x1.42x2.96x3.04x1.77x
Goodwill0000000000000000000000000000000
Intangible Assets00000000000000000000188K377K1.13M3.82M6.68M9.55M12.41M15.3M000
Long-Term Investments149.78M41.29M94.52M43.3M028.65M63.39M19.65M18.58M14.24M13.95M32.66M18.93M0032.13M34.41M56M1M55K220K331K489K401K0000000
Other Non-Current Assets7.9M8.1M4.08M4.7M5.39M4.8M1.53M1.35M585K0000195K410K1.05M1.06M2.67M2.59M1.39M1.17M2.47M3.88M804K772K11.4M63.34M4.2M16.4M200K800K
Total Assets534.12M570.54M593.78M394.08M190.57M226.03M270.73M165.52M185.28M110.31M130.25M148.76M172.51M67.34M99.8M160.05M233.58M180.38M176.22M218.9M220.8M201.24M131.87M118.11M60.67M96.23M114.03M63.7M44.5M26.1M28.8M
Asset Turnover0.35x0.32x0.13x0.00x0.00x0.01x0.00x0.00x0.01x0.01x0.05x0.24x0.01x0.02x0.03x0.02x0.02x0.01x0.02x0.03x0.01x0.00x0.01x0.01x0.02x0.04x0.06x0.08x0.15x0.28x0.18x
Asset Growth %42.11%-3.91%50.68%106.78%-15.69%-16.51%63.57%-10.67%67.96%-15.31%-12.44%-13.77%156.16%-32.52%-37.64%-31.48%29.49%2.36%-19.5%-0.86%9.72%52.6%11.65%94.69%-36.95%-15.61%79.01%43.15%70.5%-9.38%-
Total Current Liabilities73.57M111.54M88.3M108.07M76.69M45.52M30.94M28.16M7.55M6.52M7.87M6.63M41.8M7.59M14.15M13.44M40.85M7.46M7.71M12.72M46.78M9.33M8.46M9.82M9.38M10.31M8.13M7.9M3.6M3.7M3.6M
Accounts Payable011.26M8.6M6.16M10.19M6.69M6.92M1.18M982K503K225K160K1.03M1.4M3.43M2.98M3.46M2.18M2.41M2.86M1.96M1.91M2.54M1.3M1.59M1.34M1.46M1.3M1.2M700K800K
Days Payables Outstanding113.44865.922.5K---50.468.4128.1721.765.596.142.3655.8249.71------------114.45-128.24-257.65-159.69-243.33
Short-Term Debt018.45M046.89M20.95M000000000000000055K2.6M5.04M5.51M825K923K1.2M900K1M1.2M
Deferred Revenue (Current)00000000000035M000350K700K27K241K1.16M2.18M477K227K543K767K00000
Other Current Liabilities73.57M80.84M43.18M13.76M11.53M8.1M8.22M4.83M3.6M2.36M001.55M2.24M5.5M7.43M28.21M897K1.18M2.9M38.5M4.89M0004.39M5.74M5.4M1.5M2M1.6M
Current Ratio6.78x4.66x5.56x3.16x2.35x4.11x6.46x5.03x21.99x14.73x14.76x17.47x3.67x8.84x6.96x9.34x4.77x15.80x21.82x16.78x4.64x20.97x14.75x11.38x5.41x6.95x4.26x5.11x7.17x6.35x6.94x
Quick Ratio6.78x4.66x5.12x3.16x2.35x4.11x6.46x5.03x22.15x14.80x14.82x17.65x3.69x8.84x7.01x9.34x4.77x15.80x21.82x16.78x4.64x20.97x14.75x11.38x5.41x6.90x4.26x5.11x7.17x6.35x6.94x
Cash Conversion Cycle549.72-8.94K----------------------------
Total Non-Current Liabilities231.44M233.13M225.16M38.06M33.88M54.1M28.84M2.2M000000000350K52K505K105K1.21M1.35M1.97M21.55M24.38M41.99M29.6M8.1M1.3M1.6M
Long-Term Debt0231.68M118.48M35.05M30.21M49.83M24.04M000000000000000645K1.15M20.52M16.59M32.44M17.1M8.1M1.3M1.6M
Capital Lease Obligations4.97M1.45M2.27M3.01M3.67M4.27M4.8M2.2M00000000000000000000000
Deferred Tax Liabilities0000000000000000000000-707K-815K0000000
Other Non-Current Liabilities231.44M0104.42M0000000000000000427K000815K1.03M7.78M9.55M12.5M000
Total Liabilities305.01M344.67M313.46M146.13M110.58M99.62M59.78M30.36M7.55M6.52M7.87M6.63M41.8M7.59M14.15M13.44M40.85M7.8M7.76M13.22M46.88M10.54M9.81M11.79M30.93M34.69M50.11M37.5M11.7M5M5.2M
Total Debt0251.57M121.72M85.9M55.75M55M29.72M2.55M000000000000055K3.25M6.19M26.02M17.42M33.36M18.3M9M2.3M2.8M
Net Debt-70.78M172.13M42.7M15.88M-1.09M20.13M19.79M-11.09M-10.84M-16.6M-13.08M-21.52M-43.06M-12.99M-22.86M-16.11M-45.97M-34.6M-109.35M-146.03M-135.88M-96.58M-6.6M-6.63M21.42M-1.35M3.37M10.5M-7.4M-1.8M-9.6M
Debt / Equity0.00x1.11x0.43x0.35x0.70x0.44x0.14x0.02x-------------0.00x0.03x0.06x0.87x0.28x0.52x0.70x0.27x0.11x0.12x
Debt / EBITDA-0.00x------------------------------
Net Debt / EBITDA1.95x------------------------------
Interest Coverage-2.40x-1.63x-8.43x-21.15x-19.62x-30.05x-101.20x----369.23x1.52x-435.00x-685.34x-294.63x-407.66x-1135.50x-491.15x-720.90x-616.07x-364.31x-81.27x-53.77x-41.01x-47.16x-34.88x-2.13x--14.00x--30.50x
Total Equity229.11M225.87M280.32M247.95M80M126.42M210.95M135.16M177.73M103.8M122.38M142.13M130.71M59.76M85.65M146.6M192.74M172.58M168.46M205.67M173.92M190.71M122.06M106.32M29.74M61.54M63.92M26.2M32.8M21.1M23.6M
Equity Growth %-64.3%-19.42%13.06%209.94%-36.72%-40.07%56.08%-23.96%71.23%-15.18%-13.89%8.73%118.74%-30.23%-41.57%-23.94%11.68%2.45%-18.1%18.26%-8.8%56.23%14.8%257.5%-51.67%-3.72%143.96%-20.12%55.45%-10.59%-
Book Value per Share0.340.340.430.430.210.390.780.711.010.650.770.870.850.470.671.181.971.962.152.772.633.292.723.431.212.783.061.692.872.003.05
Total Shareholders' Equity229.11M225.87M280.32M247.95M80M126.42M210.95M135.16M177.73M103.8M122.38M142.13M130.71M59.76M85.65M146.6M192.74M172.58M168.46M205.67M173.92M190.71M122.06M106.32M29.74M61.54M63.92M26.2M32.8M21.1M23.6M
Common Stock0640K606K545K390K324K310K200K186K160K159K159K157K131K130K131K123K92K81K76K70K65K52K39K25K24K22K0000
Retained Earnings0-1.86B-1.77B-1.6B-1.41B-1.27B-1.16B-1.08B-1.01B-985.84M-957.92M-928.39M-928.43M-892.76M-854.38M-785.5M-688.65M-577.27M-506.89M-444.87M-399.09M-369.6M-336.07M-255.67M-225.78M-191.88M-149.8M-104M-57.5M-46.1M-36.5M
Treasury Stock0000000000000000000000000000000
Accumulated OCI0269K261K185K-219K-173K78K132K-183K-207K-53K-213K-84K-14K40K-91K-96K-406K40K33K-213K-860K-883K-744K-598K-202K-314K-1M-4.8M-3.7M-2.5M
Minority Interest0000000000000000000000000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Capital intensive commercial ramp

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Balance Sheet Erosion Amid Commercialization

As reported in recent financial statements, Geron's total assets have fluctuated significantly, reaching $534.1 million in 2026Q1, while the persistent accumulation of a $1.9 billion deficit in retained earnings underscores the long-term capital intensity required to bring their lead asset, imetelstat, to the commercial market.

The trajectory of the balance sheet reflects a company in the early stages of a high-stakes commercial transition where asset growth is increasingly offset by operational cash consumption. Investors should monitor whether the recent revenue expansion can eventually stabilize the asset base without requiring further dilutive financing.

Leverage Dynamics and Refinancing Risks

Based on the provided quarterly data, Geron's debt profile has shifted from $85.9 million in 2023Q4 to a peak of $251.6 million in 2025Q4 before being eliminated by 2026Q1, suggesting a volatile approach to capital structure management during the critical Rytelo launch phase.

The rapid deleveraging observed in the most recent quarter may indicate a strategic effort to clean up the balance sheet, yet the underlying reliance on external capital remains a structural concern. This volatility suggests that the company's ability to maintain a debt-free status is highly contingent on the success of its commercial adoption curve.

Tight Liquidity Buffers Constrain Operations

According to recent SEC filings, Geron's cash and equivalents stood at $70.8 million as of 2026Q1, a figure that appears insufficient given the company's ongoing negative operating margins and the substantial capital requirements needed to support the full-scale commercial launch of their primary therapeutic asset.

While the current ratio of 6.78 suggests a superficial level of liquidity, the actual cash runway appears limited when measured against the high burn rate associated with commercial infrastructure. This liquidity position warrants close investigation, as it may necessitate further capital raises to sustain operations through the next phase of growth.

Equity Quality Diluted by Losses

As indicated by the financial statements, equity has remained under pressure, totaling $229.1 million in 2026Q1, primarily due to the massive $1.9 billion accumulated deficit that reflects decades of R&D investment and the inherent risks of the biotechnology development cycle.

The quality of equity is currently compromised by the lack of retained earnings, which forces the company to rely on external equity markets for survival. Investors should consider that any future capital needs will likely result in further dilution, potentially impacting the long-term value proposition for existing shareholders.

GERN — Frequently Asked Questions

Quick answers to the most common questions about buying GERN stock.

What are the total assets of Geron Corporation (GERN)?

As of 2025, Geron Corporation (GERN) had total assets of $570.5M including $520.3M in current assets.

How much debt does Geron Corporation (GERN) have?

Geron Corporation (GERN) carries total debt of $251.6M, offset by $359.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Geron Corporation?

Geron Corporation (GERN) has total shareholders' equity (book value) of $225.9M ($0.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Geron Corporation's current ratio and liquidity?

Geron Corporation (GERN) reported a current ratio of 4.66x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.